| Literature DB >> 29795274 |
Erja Metsämarttila1, Enrique Rodilla2,3, Jari Jokelainen4, Sauli Herrala4, Juhani Leppäluoto1, Sirkka Keinänen-Kiukaanniemi4,5, Karl-Heinz Herzig6,7,8.
Abstract
Carotid-femoral pulse wave velocity ((cf)PWV) is a measure of arterial stiffness, predicting cardiovascular disease. We hypothesized that the amount of physical activity (PA) is correlated with reduced arterial stiffness in Type 2 diabetic (T2D) subjects. 570 subjects from the 1945 Oulu birth cohort were included in the analysis. (cf)PWV was determined by a non-invasive applanation tonometry. Oral glucose tolerance test was performed and LDL and HDL cholesterol analyzed. PA was registered daily with a wrist-worn acceleration meter for two weeks. (cf)PWV values in subjects with impaired glucose metabolism (IGM) and T2D were higher than in normal glycemic subjects (P < 0.001). PA, fasting and 2 h glucose and HbA1c correlated significantly with (cf)PWV, but HDL or LDL cholesterol did not. The 2 h glucose, heart rate and alcohol consumption in T2D subjects had independent effects on (cf)PWV in multiple regression analysis. T2D and IGM were significantly associated to (cf)PWV. Interestingly, lipids did not have an additional effect on (cf)PWV. Subjects walking more than 10 000 steps/day had 0.2 m/s lower (cf)PWV than those walking less than 6000 steps/day. Presence of T2D, elevated heart rate and alcohol consumption in males were associated with increased aortic stiffening in elderly subjects.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29795274 PMCID: PMC5966452 DOI: 10.1038/s41598-018-25755-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of the study participants.
Anthropological and biochemical characteristics of the study population. Means ± standard deviations or numbers of subjects.
| Total | NGM | IGM | T2D | P value | |
|---|---|---|---|---|---|
| No of subjects | 570 | 244 | 207 | 119 | |
| Gender (m) | 232 (41%) | 88 (36%) | 82 (40%) | 62 (52%) | 0.014 |
| Age (years) | 68.5 ± 0.6 | 68.5 ± 0.7 | 68.5 ±0 .6 | 68.5 ± 0.6 | 0.507 |
| Weight (kg) | 75.0 ± 13.6 | 71.4 ± 12.5 | 75.0 ± 12.6 | 82.3 ± 14.7 | <0.001 |
| Height (m) | 166 ± 8 | 166 ± 8 | 165 ± 8 | 166 ± 8 | 0.362 |
| BMI (kg/m2) | 27.3 ± 4.0 | 25.9 ± 3.4 | 27.5 ± 3.9 | 29.7 ± 4.2 | <0.001 |
| Obese subjects | 136 (24%) | 25 (10%) | 52 (25%) | 59 (50%) | <0.001 |
| Alcohol (g/d) | 1.7 ± 4.5 | 1.1 ± 1.8 | 2.4 ± 6.6 | 2.1 ± 3.7 | 0.273 |
| Self-reported smoking | 0.001 | ||||
| Current | 67 (12%) | 25 (10%) | 20 (10%) | 22 (19%) | |
| Former | 185 (33%) | 67 (27%) | 69 (33%) | 49 (42%) | |
| Non-smokers | 308 (54%) | 149 (61%) | 113 (55%) | 46 (39%) | |
| SP (mmHg) | 142 ± 18 | 141 ± 18 | 143 ± 17 | 144 ± 19 | 0.188 |
| DP (mmHg) | 78 ± 8 | 77 ± 8 | 79 ± 8 | 78 ± 8 | 0.158 |
| No of HT | 235 (41%) | 70 (29%) | 96 (46%) | 69 (58%) | <0.001 |
| No of CAD | 60 (11%) | 14 (6%) | 19 (9%) | 27 (23%) | <0.001 |
| Antihypertensive medication | 249 (50%) | 80 (37%) | 94 (55%) | 75 (67%) | <0.001 |
| Lipid lowering medication | 167 (33%) | 51 (/24%) | 65 (38%) | 51 (46%) | <0.001 |
| Diabetes medication | 62 (11%) | 62 (11%) | <0.001 | ||
| Daily steps | 8877 ± 3683 | 9419 ± 3629 | 8707 ± 3481 | 8062 ± 3977 | 0.001 |
| Fasting glucose (mmol/l) | 5.6 ± 0.6 | 5.4 ± 0.4 | 5.7 ± 0.5 | 6.2 ± 0.8 | <0.001 |
| 2 h glucose (mmol/l) | 6.9 ± 1.9 | 5.6 ± 1.1 | 7.6 ± 1.4 | 9.3 ± 2.4 | <0.001 |
| HbA1c (mmol/l) | 40.5 ± 5.2 | 38.7 ± 3.5 | 40.1 ± 3.9 | 44.9 ± 7.1 | <0.001 |
| Total cholesterol (mmol/l) | 5.4 ± 1.2 | 5.5 ± 1.2 | 5.4 ± 1.1 | 5.0 ± 1.4 | <0.001 |
| HDL cholesterol (mmol/l) | 1.7 ± 0.5 | 1.8 ± 0.5 | 1.6 ± 0.4 | 1.5 ± 0.4 | <0.001 |
| LDL cholesterol (mmol/l) | 3.4 ± 1.1 | 3.5 ± 1.1 | 3.4 ± 1.0 | 3.2 ± 1.3 | 0.007 |
| (cf)PWV (m/s) | 8.8 ± 1.8 | 8.3 ± 1.7 | 9.0 ± 1.9 | 9.4 ± 1.7 | <0.001 |
| MBP adj. (cf)PWV (m/s) | 8.8 ± 1.6 | 8.4 ± 1.5 | 9.0 ± 1.8 | 9.3 ± 1.5 | <0.001 |
P values calculated with Kruskal-Wallis rank sum test or chi-square test between the groups. The Total column is not part of the calculations.
NGM, normal glucose metabolism; IGM, impaired glucose metabolism; T2D, type 2 diabetes; BMI, body mass index; SP, brachial systolic blood pressure; DP, brachial diastolic blood pressure; HT, hypertension; No, number of; CAD, coronary artery disease; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; (cf)PWV, carotid-femoral pulse wave velocity; MBP, mean blood pressure.
Multiple regression analysis of the cohort. Dependent variable (β, beta coefficient; CI confidence intervals).
| Model 1 | Model 2 | Model 3 | Model 4 | |
|---|---|---|---|---|
| (1) n = 570 | (2) n = 570 | (3) n = 476 | (4) n = 476 | |
| IGM | 0.548 (0.252, 0.845) | 0.457 (0.162, 0.751) | 0.221 (−0.108, 0.550) | 0.203 (−0.127, 0.533) |
| T2D | 0.920 (0.569, 1.271) | 0.840 (0.491, 1.189) | 0.626 (0.211, 1.042) | 0.586 (0.166, 1.007) |
| HR | 0.038 (0.022, 0.055) | 0.038 (0.019, 0.057) | 0.039 (0.020, 0.058) | |
| Gender | 0.107 (−0.159, 0.374) | 0.026 (−0.322, 0.374) | 0.030 (−0.318, 0.378) | |
| Alcohol consumption (g alcohol/day) | 0.067 (0.018, 0.116) | 0.069 (0.020, 0.119) | ||
| Obesity (BMI) | 0.341 (−0.027, 0.710) | 0.318 (−0.052, 0.689) | ||
| PA (1000 steps) | −0.016 (−0.056, 0.025) | −0.014 (−0.055, 0.026) | ||
| Smoking (former) | −0.222 (−0.553, 0.109) | −0.231 (−0.562, 0.100) | ||
| Smoking (current) | −0.383 (−0.855, 0.089) | −0.388 (−0.860, 0.084) | ||
| HDL cholesterol (mmol/l) | −0.107 (−0.480, 0.266) | −0.095 (−0.469, 0.279) | ||
| Triglycerides (mmol/l) | 0.029 (−0.142, 0.200) | 0.032 (−0.139, 0.203) | ||
| Anti –Hypertension medication | 0.172 (−0.123, 0.467) |
Note: *p < 0.05; **p < 0.01; ***p < 0.001.
IGM, impaired glucose metabolism; T2D, type 2 diabetes; HR, heart rate; PA, physical activity, Model 1 includes IGM and T2D; Model 2 includes Model 1 variables plus HR, and Model 3 includes variables from Model 1 & 2 and alcohol consumption, obesity; Model 4 included variables from Model 1–3 and anti-hypertensive medication.
Figure 2Associations between pulse wave velocity ((cf)PWV) and fasting glucose (A) and 2 h glucose (B) and glycated hemoglobin (HbA1c) (C). Shaded area represents 95% CIs around the regression line.
Figure 3Boxplot presentation of pulse wave velocity ((cf)PWV) in normal glucose metabolism (NGM), impaired glucose metabolism (IGM) and type 2 diabetes (T2D). The horizontal lines represent the median values, the boxes interquartile ranges, error bars 95% confidence intervals. ***P < 0.001, *P < 0.05.
Figure 4Associations between pulse wave velocities ((cf)PWV) and total (A), LDL (B) and HDL (C) cholesterol. Shaded area represents 95% CIs around the regression line.
Figure 5(A) Linear correlation between physical activity (steps/day) and pulse wave velocity ((cf)PWV). Shaded area represents 95% CIs around the regression line (B) Differences in (cf)PWV in physical activity quartiles. The horizontal lines represent the median values, the boxes interquartile ranges, error bars 95% confidence intervals. Outside values are presented. *P < 0.05.